

บรรณานุกรม

1. The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, 12th ed. Merck & Co., Inc. Whitehouse Station, NJ, U.S.A., 1996.
2. Reeves DS. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin. *Lancet* 1971; 1:261-264.
3. Tally FP, Lovie TJ, Weinstein UM, Bartlett JG, Gorbach SL. Amikacin therapy for severe gram-negative sepsis, emphasis on infections with gentamicin-resistant organisms. *Ann Intern Med* 1975; 83:484-8.
4. Brewer NS. Antimicrobial agents - part II. The aminoglycosides streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin. *Mayo Clin Proc* 1977;52:675-9.
5. Baker CE Jr (Publisher). Physicians' Desk Reference, New Jersey: Litton Industries 1981; 35th ed. 1098.
6. Cook FV, Farrar Jr, WW. Vancomycin revisited. *Ann Intern Med* 1978;88:813-8.
7. Jordan DC, Reynolds PE. Vancomycin. *Antibiotics* 1978;3:704-18.
8. Anhalt JP. Laboratory monitoring of antimicrobial therapy. American Association for Clinical Chemistry Therapeutic Drug Monitoring Continuing Education and Quality Control Program 1981; April:1-11.
9. Nordstrom L, Banck G, Belfrage S, Juhlin I, Tjernstrom O, Toremalm NG. Prospective study of the ototoxicity of gentamicin. *Acta Pathol Microbiol Immunol Scand(B)* (Supp 241) 1973:58-61.
10. Dayal VS, Smith EI, McCain WG. Cochlear and vestibular gentamicin toxicity. A clinical study of systemic and topical usage. *Arch Otolaryngol* 1974;100:338-40.
11. Appel GB, Neu HD. The nephrotoxicity of antimicrobial agents. *N Engl J Med* 1977;296:772-8.
12. Geraci JE. Vancomycin. *Mayo Clin Proc* 1977;52:631-4.
13. Barza M, Lauermann M. Why monitor serum levels of gentamicin? *Clin Pharmacokinet* 1978;3:202-15.

14. Mangione A, Schentag JJ. Therapeutic monitoring of aminoglycoside antibiotics: An approach. *Ther Drug Monit* 1980;2:159-67.
15. Arneil GC, Murdock JM (Chairmen). Scottish Gentamicin Symposium Glasgow. *Scott Med J* 1975;20:141-4.
16. Russo Me. Penicillin-aminoglycoside inactivation; another possible mechanism of interaction. *Am J Hosp Pharm* 1980;37:702-704.
17. McLaughlin JE. Gentamicin plus carbenicillin. *Lancet* 1971;1:864-865.
18. Winters RE, Hewitt WL. combined use of gentamicin and carbenicillin. *Ann Intern Med* 1971;75:925-927.
19. Pickering LK, Gearhart P. Effect of time and concentration upon interaction between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin. *Antimicrob Agents Chemother* 1979;15:592-596.
20. Noone P, Pattison JR. Therapeutic implications of interactions of gentamicin and penicillin. *Lancet* 1971; 2:575-578.
21. Bobrow SN, Jaffe E, Young RC. Anuria and acute tubular necrosis associated with gentamicin and cephalothin. *JAMA* 1972;222:1546-1547.
22. Kleinknecht D, Ganeval D, Droz D. Acute renal failure after high doses of gentamicin and cephalothin (letter). *Lancet* 1973;1:1129.
23. Eykyn S, Phillips I, Ridley M. Gentamicin plus carbenicillin. *Lancet* 1971;1:545-546.
24. Welbert RT, Keane WF. Carbenicillin-gentamicin interaction in acute renal failure. *Am J Hosp Pharm* 1977;34:1137-1139.
25. Tindula RJ, Ambrose PJ, Harralson AF. Aminoglycoside inactivation by penicillins and cephalosporins and its impact on drug-level monitoring. *Drug Intell Clin Pharm* 1983;17: 906-8.
26. Pickering LK, Rutherford I. Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin and piperacillin. *J Pharmacol Exp Ther* 1981;217:345-9.
27. Hale DC, Jenkins R, Matsen JM. In vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin. *Am J Clin Pathol* 1980;74:316-319.



มหาวิทยาลัยราชภัฏวชิร

มหาวิทยาลัยราชภัฏวชิร

- 20 -

28. TDx Assays Manual, Abbott Laboratories, Abbott Park, IL 60064, U.S.A., 1992.
29. Farchione LA. Inactivation of aminoglycosides by penicillins. *J Antimicrob Chemother* 1981;8:27-36.
30. Jorgensen JH, Crawford SA. selective inactivation of aminoglycoside by newer beta-lactam antibiotics. *Curr Ther Res Clin Exp* 1982;32:25-35.